Tarenflurbil
3 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
3
Ongoing
0
Recruiting
0
Completed
1
Sites
284
Countries
12
Endpoints
5
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 5 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 0 of 5 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
No normalized metric codes are available for this asset.
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT00105547Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's | Tarenflurbil Alzheimer’s disease | Alzheimer's disease | Ph 3 | Completed | 132 | May 2008 | 1 | |
| NCT00322036Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's | Tarenflurbil Alzheimer’s disease | Alzheimer's disease | Ph 3 | Terminated | 92 | Dec 2008 | - | |
| NCT00380276Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol | Tarenflurbil Alzheimer’s disease | Alzheimer's disease | Ph 3 | Terminated | 90 | Dec 2008 | - |
Showing 1-3 of 3 trials